Back to search results

Extended Bupropion Treatment for Smoking Cessation in African Americans

This study is looking at whether taking bupropion (a medication to help you stop smoking) for a longer time (6 months) works better than the standard treatment time (7 weeks) for African American daily smokers. You could be eligible if you are an African American adult over 18, smoke more than one cigarette a day, are interested in quitting, and are willing to take the study medication and attend all appointments. The main goal is to see if more people can successfully quit smoking by Month 6 with the extended treatment. The current status of this study is unclear.

Study design
This study will randomly assign 500 participants to receive either 6 months or 7 weeks of bupropion. All participants will also receive smoking cessation counseling.
What's involved
You would take bupropion daily for either 7 weeks or 6 months and complete all study visits. You would also receive individualized smoking cessation counseling.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through Month 12 to check on their smoking status.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05732272

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Recruiting
PHASE3Ages 18+InterventionalTreatment
University of Kansas Medical Center
~500 participants
Updated 2026-02-23 on ClinicalTrials.gov
What's tested:Bupropion

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Verified abstinence at Month 6
Measured over Month 6

Conditions

Smoking Cessation

Explore related trials

Smoking Cessation

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Lisa Sanderson Cox, PhD · PRINCIPAL_INVESTIGATOR · University of Kanas Medical Center

Who to contact

Tricia Snow, MPH
[email protected]
816-398-8960
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

African American
age \>18 years
interested in quitting
smoked \>1 cpd for \>1 years
smoked on \>25 days in the past month
willing to take 6 months of study medication and complete all visits
have a home address and functioning telephone number

Exclusion

Consistent with contraindications for bupropion:
use of psychoactive medications
history of alcohol or substance abuse within the past year
binge drinking (\>5 drinks on one occasion) \>2 times in the past month
history of seizures or head trauma; history of bulimia or anorexia nervosa
pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding
myocardial infarction in the past 2 months
reported use of opiates, cocaine, or stimulants
unstable diabetes
bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded.
use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days
planning to move from the Kansas City area in the next year
other smoker in household enrolled in the study.

What this trial measures

  • Verified abstinence at Month 6Month 6

    Participants receiving extended bupropion treatment will have significantly higher Month 6 verified point-prevalence abstinence than participants receiving standard bupropion treatment.